CK1α-Targeting Isoindoline Carboxamides for Refractory AML
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for safe and effective methods to treat and prevent acute myeloid leukemia (AML), particularly for refractory cases that are resistant to standard treatments like chemotherapy, radiation therapy, and biological therapy, while minimizing toxicities and side effects.
Innovation Solution
Development of 1-oxo-isoindoline-5-carboxamide compounds that target Casein kinase-1α (CK1α) to reduce protein levels, thereby treating or preventing AML through pharmaceutical compositions suitable for various administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy treatments (cytarabine and anthracycline combination) are used to induce remission in AML, then remission can be achieved in many patients, but treatment-related mortality increases and toxicities occur
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (CK1α kinase activity) that drives AML pathogenesis, separating the therapeutic action from the non-specific cytotoxic effects of conventional chemotherapy. By designing compounds that specifically inhibit CK1α, the treatment achieves anti-leukemic effects while avoiding the broad tissue damage that causes treatment-related mortality and toxicities
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediaries that block the CK1α kinase enzyme, preventing its pro-leukemic signaling functions. These compounds act as mediators between the administered drug and the disease process, selectively interfering with the kinase pathway without directly damaging healthy cells, thus reducing toxicities while maintaining remission induction effectiveness
2Reliability
If intensive chemotherapy is administered to achieve remission, then complete remission rates improve, but the complexity of treatment protocols and patient management increases
Solution Approach 1:
The patent extracts the essential therapeutic function from complex multi-agent chemotherapy protocols and concentrates it into a single targeted molecular intervention. By focusing on CK1α inhibition as the key mechanism, the treatment achieves remission induction without requiring complex combination regimens, thereby simplifying the treatment protocol while maintaining effectiveness
Solution Approach 2:
The patent designs CK1α inhibitors with broad applicability across different AML subtypes and patient populations, including those with secondary AML and myelodysplastic syndromes. This universal mechanism replaces the need for highly customized complex protocols, providing a simplified yet effective treatment approach for diverse patient groups
3Object-affected harmful factors
If low-dose cytarabine or supportive care is used in elderly or unfit AML patients, then treatment-related toxicities are reduced, but therapeutic effectiveness decreases
Solution Approach 1:
The patent changes the fundamental parameter of therapeutic action from non-specific cytotoxicity to specific kinase inhibition. This parameter change allows the treatment to achieve therapeutic effectiveness through mechanism-based selectivity rather than dose-dependent cytotoxicity, enabling effective treatment in elderly and unfit patients without requiring high doses that would cause unacceptable toxicities
Data Source
AI summary
Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure:wherein R1, R2, R3, R4 and n are as defined herein, compositions comprising an effective amount of a 1-oxo-isoindoline-5-carboxamide compound, and methods for treating or preventing disorders.